Juno Therapeutics
E387620
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Juno Therapeutics canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T3803134 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Juno Therapeutics Context triple: [Stuart L. Schreiber, coFounderOf, Juno Therapeutics]
-
A.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
B.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
E.
Janssen Biotech
Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Juno Therapeutics Target entity description: Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
A.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
B.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
E.
Janssen Biotech
Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
biotechnology company ⓘ cancer immunotherapy company ⓘ |
| acquiredBy | Celgene ⓘ |
| acquisitionDate | 2018 ⓘ |
| acquisitionValue | approximately 9 billion US dollars ⓘ |
| collaboratesWith |
Celgene
ⓘ
Fred Hutchinson Cancer Center ⓘ
surface form:
Fred Hutchinson Cancer Research Center
Memorial Sloan Kettering Cancer Center ⓘ Seattle Children’s Hospital ⓘ
surface form:
Seattle Children’s Research Institute
|
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
TCR-based therapies
ⓘ
cell-based cancer therapies ⓘ chimeric antigen receptor T cell therapies ⓘ |
| focusesOn |
CAR-T cell therapy
ⓘ
T cell engineering ⓘ cancer immunotherapy ⓘ immuno-oncology ⓘ |
| founded | 2013 ⓘ |
| foundedBy |
Hans Bishop
ⓘ
Juno co-founders group ⓘ Larry Corey ⓘ Phil Greenberg NERFINISHED ⓘ Richard Klausner ⓘ S. Rafi Ahmed ⓘ Stan Riddell ⓘ |
| hasKeyPerson |
Hans Bishop
ⓘ
Larry Corey ⓘ Richard Klausner ⓘ |
| headquartersLocation | Seattle, Washington, United States ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| ipoDate | 2014 ⓘ |
| listedOn | NASDAQ ⓘ |
| originatesFrom |
Fred Hutchinson Cancer Center
ⓘ
surface form:
Fred Hutchinson Cancer Research Center
Memorial Sloan Kettering Cancer Center ⓘ Seattle Children’s Hospital ⓘ
surface form:
Seattle Children’s Research Institute
|
| parentOrganization |
Bristol Myers Squibb
ⓘ
Celgene ⓘ |
| productCandidate |
JCAR014
ⓘ
JCAR015 ⓘ JCAR017 ⓘ |
| researchArea |
hematologic malignancies
ⓘ
leukemia ⓘ lymphoma ⓘ |
| therapeuticTarget |
BCMA
ⓘ
CD19 ⓘ |
| tickerSymbol | JUNO ⓘ |
| usesTechnology |
chimeric antigen receptor (CAR) technology
ⓘ
genetic engineering of T cells ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Juno Therapeutics Description of subject: Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.